243 related articles for article (PubMed ID: 33776703)
1. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.
Makimoto G; Kawakado K; Nakanishi M; Tamura T; Kuyama S
Case Rep Oncol; 2021; 14(1):197-201. PubMed ID: 33776703
[TBL] [Abstract][Full Text] [Related]
2. Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y; Shukuya T; Murata A; Kikkawa H; Emir B; Wiltshire R; Miura S
Cancer Sci; 2023 Jun; 114(6):2560-2568. PubMed ID: 36866958
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis.
Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Sagara H
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359604
[TBL] [Abstract][Full Text] [Related]
4. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with
Myall NJ; Lei AQ; Wakelee HA
Transl Lung Cancer Res; 2021 Jan; 10(1):487-495. PubMed ID: 33569330
[TBL] [Abstract][Full Text] [Related]
5. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer.
Wang WQ; Xu T; Zhang JJ; Wang Y; Wang Y; Zhang W; Zhu JG
J Thorac Dis; 2023 Apr; 15(4):1935-1947. PubMed ID: 37197536
[TBL] [Abstract][Full Text] [Related]
7. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
Karachaliou N; Fernandez Bruno M; Bracht JWP; Rosell R
Onco Targets Ther; 2019; 12():4567-4575. PubMed ID: 31354290
[TBL] [Abstract][Full Text] [Related]
8. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
9. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
Yun KM; Bazhenova LA
Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
[TBL] [Abstract][Full Text] [Related]
10. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
11. Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report.
Sasaki K; Yokota Y; Isojima T; Fujii M; Hasui K; Chen Y; Saito K; Takahata T; Kindaichi S; Sato A
Respirol Case Rep; 2021 Jul; 9(7):e00796. PubMed ID: 34123384
[TBL] [Abstract][Full Text] [Related]
12. Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC.
Hashimoto H; Komori K; Kameda K; Taguchi S; Ozeki Y
Surg Case Rep; 2022 Apr; 8(1):59. PubMed ID: 35366157
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
Kashizaki F; Tanaka A; Sekido Y
J Med Case Rep; 2022 Aug; 16(1):316. PubMed ID: 35999557
[TBL] [Abstract][Full Text] [Related]
14. Liver and Pancreatic Injury in Response to ALK Inhibitors in a Patient with Primary Signet Ring Cell Carcinoma of the Lung: A Case Report.
Yildiz I
Case Rep Oncol; 2021; 14(1):107-111. PubMed ID: 33776691
[TBL] [Abstract][Full Text] [Related]
15. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
Chuang CH; Chen HL; Chang HM; Tsai YC; Wu KL; Chen IH; Chen KC; Lee JY; Chang YC; Chen CL; Tu YK; Hung JY; Yang CJ; Chong IW
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921762
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Fan J; Fong T; Xia Z; Zhang J; Luo P
Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
[TBL] [Abstract][Full Text] [Related]
18. Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.
Singh A; Chen H
Cancer Manag Res; 2020; 12():6615-6628. PubMed ID: 32821158
[TBL] [Abstract][Full Text] [Related]
19. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
[TBL] [Abstract][Full Text] [Related]
20. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]